November 22nd, 2011
Merck Pleads Guilty and Pays $950 Million for Illegal Promotion of Vioxx
Larry Husten, PHD
The US Department of Justice announced today that Merck, Sharp & Dohme will plead guilty to illegal promotion of Vioxx (rofecoxib) and will pay a $950 million in fines and penalties to the US government and individual states.
September 29th, 2011
Meta-Analysis Explores Real World CV Risk of NSAIDs
Larry Husten, PHD
A new meta-analysis sheds additional light on the cardiovascular risk of NSAIDs as used in the real world, including low doses of the most popular drugs, over short periods, and in low-risk populations. In a paper published online in PLoS Medicine, Patricia McGettigan and David Henry analyzed data from 30 case-control studies including 184,946 CV events and […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?